Why is morphine-6-glucuronide clinically relevant in morphine therapy?

• A. M6G is an inactive metabolite with no analgesic activity
• B. M6G is an active metabolite with potent analgesic activity contributing to morphine's efficacy, especially in renal impairment
• C. M6G is only toxic and has no analgesic effects
• D. M6G reduces morphine clearance

Answer: (C)

Morphine-6-glucuronide is an active metabolite that contributes meaningfully to morphine’s analgesic effect. It binds mu-opioid receptors and can provide potent pain relief, sometimes with greater potency per dose than morphine itself. Its clearance relies heavily on renal excretion, so in patients with renal impairment M6G can accumulate, leading to enhanced analgesia but also a higher risk of adverse effects such as respiratory depression and sedation. This makes M6G clinically relevant in morphine therapy, because dosing may need adjustment in kidney dysfunction to balance analgesia with safety. In contrast, morphine-3-glucuronide is not analgesic and may be linked to other effects, so the key point about M6G is its active analgesic role and its potential for accumulation in renal failure.